Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 11 most popular AI penny stocks to buy now. On February 25, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) reported Q4 revenue of $35.5 million ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. If you are wondering whether Recursion Pharmaceuticals is ...

Shares of Recursion Pharmaceuticals RXRX are surging Wednesday following a robust earnings report released before the bell. The biotechnology firm reported a loss per share of 21 cents, surpassing the ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Based on the one-year price targets offered by 7 analysts, the average target price for Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is $7.00, with a high estimate of $11.00 and a low estimate of $3.00 ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

How a game looks is one of its most important factors, especially in an age of photo-realism and ray-tracing. So, even if you're playing one of the most aesthetically uncomplicated videogames to come ...

DALLAS — This weekend the streets of Arlington surrounding AT&T Stadium and Globe Life Field will play host to a different kind of sport than fans are used to seeing around those parts. Starting ...